. Cefuroxime inhibits Gram negative bacilli at appreciably low MIC values, showing activity against strains which, to some extent, have been resistant to the other cephalosporins (Eykyn et al. 1976) . It is more active than cephalothin against most species of Gram negative organisms (Goodwin et al. 1977 ). In the present study, we have investigated the clinical efficacy and pharmacokinetics of cefuroxime in 64 patients with various bacterial infections.
Patients and Methods
Sixty-four inpatients with various bacterial infections were selected for treatment with cefuroxime. Thirty-four of these patients had urinary tract infection (UTI), 19 respiratory tract infection, 5 otitis media, 5 soft tissue infection and 1 septicmmia. Their age and sex distribution is shown in Table 1 . The majority of the patients with UTI were get iatric patients.
The UTI diagnosis was based on a significant growth of bacteria (>105/ml) obtained from a mid-stream specimen. In otitis media, the specimen was a puncture sample taken from the middle ear and in pneumonia, the causative bacterium was isolated either from a transtracheal puncture sample or from sputum. Tables 2, 3 and 4 show the isolated strains of bacteria.
In UTfs, the dose of cefuroxime was 500 mg given 3 times daily i.m. for 7 days in 16 patients and 750 mg given 3 times daily i.m. for 7 days in 18 patients. In the other infections, the dose was 500 mg given 3 times in 24 In preliminary trials, cefuroxime, a new injectible cephalosporin, has been found to have advantages over existing derivatives. In addition to its stability to staphylococcal penicillinase, cefuroxime is stable to most of the 3-lactamases produced by Gram negative bacilli . Its activity is good against most Gram positive bacteria and it is also active against a wide range of Gram negative organisms (Verbist In order to detect any side effects, the following tests were performed before, during and after treatment: blood sugar, hemoglobin, packed cell volume, total red cells, total white cells and typing of leucocytes, thrombocytes, blood urea, serum creatinine, bilirubin, alkaline phosphatase, serum glutamic oxaloacetic transaminase, lactic dehydrogenase and urinary sediment.
The standard bacteriological techniques were used for the isolation and identification of microorganisms in the clinical samples. Sensitivity to cefuroxime was determined by the disc method Concentrations of cefuroxime in urine, serum and sputum were determined by the cylinderplate method (Grove & Randall 1955) with Bacillus subtilis MB32 SDR as a test organism. Sputum samples were homogenized, then liquefied by adding an equal volume of 1 % pancreatic solution and incubated for I h at 37°C before assay.
RESULTS

Pharmacological Findings
Concentrations of 29-1680 ,ug/ml were measured in urine within 6 h of the administration of a single 500 mg dose. Within 6 h of the administration of the single 750 mg dose, the urine concentrations were 20-2211 jug/ml (Table 5) . Table 6 shows the serum concentrations after the i.m. administration of 500 mg of cefuroxime 3 times daily. Mean age (±s.d.) of these 8 female patients was 68.0±22.5 years and mean body weight (±s.d.) was 57.6±14.5 kg. The results show that 8 h after the first injection, the cefuroxime concentration was always ;-0.6 ,ug/ml. A cumulative tendency in serum concentration was observed in I patient (Table 6 , patient LS). Table 7 shows the serum concentration after the thrice daily administration of 750 mg. The concentrations are somewhat higher than those observed after the 500 mg doses. Likewise, a cumulative tendency was found in at least 2 patients (Table 7 , patients LN and AJ). Concentration of cefuroxime in the sputum was studied in 5 patients treated with three daily i.m. injections of 500 mg cefuroxime. The concentrations observed (8 samples in total) varied from 0.28-1.29 tg/ml.
Clinical Results
The results in our geriatric patients with UTI who received 500 mg of cefuroxime 3 times daily were very poor. Only 7 of the 16 patients had sterile urine after treatment (Table 2 ). In this group UTI was usually recurrent, and organisms were hospital strains with poor response in general. The zone diameter and clinical results had a fair correlation. When using the larger dose of cefuroxime, 750 mg given 3 times daily, sterile urine was achieved in the other group of patients in 13 (Table 3) .
The detailed results of the other infections are shown in Table 4 and summarized in Table 8 . In these tables unsatisfactory means that after cefuroxime the treatment had to be continued with some other antibiotic. Improved means that the irritative phase of bronchitis or pneumonia had passed and that the patient still had some signs of inflammation, but a renewed course of antibiotics was not required. The term cured applies to a complete disappearance of all symptoms and signs of infection during the treatment. Only 2 patients required additional antibacterial treatment. These patients had complicated pneumonia. One had Proteus vulgaris the other an Escherichia coli -Klebsiella combination in the transtracheal puncture sample. The results in children with otitis media were also good.
Side Effects
Patients did not have any subjective side effects. The injections were painless and well tolerated. For all the patients with UTI, the laboratory tests gave normal results. By contrast, 43% of the patients with other infections, whose tests were performed in the same laboratory, showed pathological changes (Table 9 ). Two patients who previously had no renal defects nor any predisposing factors developed mild azotaemia which was cured during the treatment. Thirteen patients Clinical resulta Table 8 Clinical results with cefuroxime in respiratory and some other infections had mild liver enzyme changes. Only one patient had a pathological value before the treatment which deteriorated further as treatment continued. Even though permanent changes did not develop, the findings are clinically noteworthy. During treatment, no changes were observed in the number of leucocytes or thrombocytes
Discussion
The maximum serum concentration of cefuroxime was achieved I h after injection and the peak value of serum concentrations was 12 ,ug/ml in the 500 mg group. This was below the value of 22.5 ,tg/ml presented by Foord (1976) . Whether this is dependent on the method of analysis or on the fact that the mean age of our patients was high and consequently their renal function was physiologically reduced remains an open question. According to Goodwin et al. (1977) 53 % of cefuroxime is excreted through the tubules and with age this tubular function is easily disturbed. Notwithstanding this, in our material the hourly means of cefuroxime concentrations in urine exceeded 390 jig/ml in a biologically active form.
For UTfs, the response with 500 mg given 3 times daily was poor in geriatric patients, but it improved substantially when the dose was increased to 750 mg given 3 times daily. By con- a=only abnormal values ar-e given; NT not tested trast, cefuroxime was effective at a daily dose of 500 mg given 3 times (and for children 30 mg/kg) in infections of the respiratory tract and of soft tissues as well as in childhood otitis.
No side effect whatever occurred in the geriatric patients with UTI, whereas in the other infections, follow-up laboratory tests revealed changes in 43 % of cases. In general, liver enzymes were elevated above normal but returned to normal after treatment. For urinary tract and other infections, the laboratory tests were performed at the same laboratory so excluding differences in the methods of analysis. In future, it will be appropriate to follow up possible changes in the liver and kidneys during treatment. From the results so far obtained, no definitive statement can be made about the clinical safety of cefuroxime.
Summary
Serum levels and urine concentrations of cefurozime were measured in adult patients after the thrice daily administration of 500 mg or 750 mg. No accumulation of the antibiotic could be observed in the course of treatment. Peak serum levels were reached 1 h after the injection, and 8 h after the 500 mg cefuroxime injection, serum levels were always >0.4 ,ug/ml. Concentrations of 29-1680 ,ug/ml were measured in urine within 6 h of the administration of the 500 mg dose and 20-2211 ,tg/ml within 6 h of the administration of the 750 mg dose.
Sixty-four patients were treated with cef-uroxime. Of these, 34 suffered urinary tract infection, 19 respiratory tract infection, 5 otitis media, 5 soft tissue infection and 1 septic-emia.
In the geriatric patients with chronic urinary tract infection, the response was poor with the 500 mg dosage three times daily. Only in 7 cases of the 16 was the urine sterile after treatment. However, with the 8 hourly dose of 750 mg, the response was clearly better and the urine was sterile in 13 of the 18 cases. With the other infections the response was good in 93 % of cases (28 out of 30). Only in 2 patients with pneumonia, one having Proteus vulgaris and one Escherichia coli and Klebsiella in the transtracheal puncture sample, was further treatment with another antibiotic considered necessary.
No side effects were reported by any of the patients during treatment. In 34 patients with UTI no changes in laboratory tests were observed. In 13 of the 30 patients with the other infections, transient abnormalities in liver enzyme values or mild azotxmia was found. Most frequently there was an increase above normal of the transaminase or alkaline phosphatase levels, which returned to normal after treatment in all patients concerned. In laboratory tests, factors predisposing to abnormalities were found in 1 case only.
We conclude that cefuroxime is an effective cephalosporin antibiotic. Our observations indicate that a careful monitoring of the liver and kidney functions is needed in patients during cefuroxime treatment. which failed to respond to cefuroxime were sensitive to other cephalosporins.
Professor Hanninen said that all the organisms were originally sensitive to cefuroxime. He agreed that the situation was one of superinfection rather than failure of the original therapy.
Dr A Pines (Hertford) had obtained similar results to those of Professor Miki. Cefuroxime gave very good results in respiratory infection but rather poor results in secondarily infected lung cancer and lung abscesses. It was strange that with cefazolin, which was not so effective against Hamophilus, the results were far better in the secondarily infected lung cancers and abscesses. According to Professor Matsumoto, cefuroxime and cefazolin had much the same degree of penetration in bronchial secretions and also comparable serum levels.
Professor M Balasegaram (Kuala Lumpur) drew attention to the fact that in Professor Miki's work the follow-up period had been relatively short and a number of the patients had developed recurrent infections. However, if this new drug was to be introduced, long-term follow up on biliary tract infection was very important.
Professor Miki agreed that long-term follow-up was indeed necessary, especially in those cases where patients had gall stones.
Dr de Meutter (Renaix) said that the incidence of pain on injection found by Professor Miki in one-third of his patients was comparable to his own experience.
Dr S M Harding (Greenford) agreed that some volunteers complained of discomfort after i.m. injection. After about I min pain was first noticed and it then built up for 3 min. In about one-third of cases it was described as moderate. Increasing the volume of injection increased the pain so that the smaller volume used when cefuroxime was given as a suspension was advantageous in this respect.
Dr J M Verstraeten (Ghent) asked why the results were so good for urinary and biliary infections but less good for respiratory disease. Was it a question of concentration, of penetration or of bacteriology ?
Dr Sterner (Chairman) noted that in Professor Miki's series the drug was effective in only twothirds of those patients with respiratory illness.
of bacterial etiology of the pneumonia was not considered necessary in this material because he believed that almost all cases of pneumonia in undernourished children were of bacterial origin. They had used 50 mg/kg body weight given as an i.m. injection three times daily. Pain on injection was absent or slight which compared favourably with cefoxitin where an antesthetic diluent had been necessary.
Dr P M Shah asked Professor Hanninen which organisms had been isolated in patients who failed to respond to 500 mg of cefuroxime three times daily for urinary tract infection.
Professor Hanninen said that there were 3 cases of Escherichia coli, I of Streptococcus farcalis, and I of Aerobacter.
Dr Shah said that they had investigated the activity of fl-lact4m antibiotics in urine. They performed MIC determinations in broth and using patients' urine as a medium. MIC values determined in urine were high for almost all Gram negative bacteria. This might explain why, although high urinary levels of the antibiotic were excreted, the patients still failed to respond.
For pneumonia the cure rate was 74% as opposed to the usually quoted 90% or 95 % antibiotic cure rate. In Sweden and Norway they had noted for many years that in only half of the hospitalized cases of primary pneumonia was the disease caused by bacterial infection. The other half was due to mycoplasmas, viral infections, or other infectious agents. These could not be cured with an antibiotic of this type but they recover later spontaneously. That was one reason why the recovery rate in most studies of respiratory illnesses presented here was about 90%. Another reason was that the investigators had tried to include only bacterial infections in their series of patients.
Professor M Balasegaram (Kuala Lumpur) said that host factors had to be taken into account when assessing the effectiveness of an antibiotic.
Dr C G Levi (Sao Paulo) said that he had treated 17 children with lower respiratory tract infection. They were all undernourished and had low resistance, but cures were obtained in 16 out of the 17. This result was better than that usually obtained with any other drug or drug combination. Patients were studied radiologically. Evidence
